STAAR Surgical (NASDAQ:STAA) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in STAAR Surgical (NASDAQ:STAA) by 2.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,174,499 shares of the medical instruments supplier’s stock after purchasing an additional 31,212 shares during the quarter. Geode Capital Management LLC owned approximately 2.38% of STAAR Surgical worth $43,641,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Van ECK Associates Corp lifted its stake in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after buying an additional 393 shares in the last quarter. Sei Investments Co. lifted its position in shares of STAAR Surgical by 2.7% in the second quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier’s stock valued at $718,000 after acquiring an additional 394 shares in the last quarter. Creative Planning boosted its stake in shares of STAAR Surgical by 8.0% during the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after acquiring an additional 408 shares during the last quarter. Louisiana State Employees Retirement System increased its position in STAAR Surgical by 2.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 24,700 shares of the medical instruments supplier’s stock worth $1,176,000 after purchasing an additional 500 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in STAAR Surgical by 7.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,291 shares of the medical instruments supplier’s stock valued at $442,000 after purchasing an additional 652 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Down 2.6 %

Shares of NASDAQ STAA opened at $24.17 on Tuesday. The stock has a market capitalization of $1.19 billion, a PE ratio of 54.93 and a beta of 0.59. The firm has a fifty day moving average of $28.17 and a 200-day moving average of $34.36. STAAR Surgical has a 52-week low of $23.72 and a 52-week high of $52.68.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 53,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was purchased at an average price of $24.24 per share, with a total value of $1,296,840.00. Following the transaction, the insider now owns 10,821,931 shares in the company, valued at $262,323,607.44. This trade represents a 0.50 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus lowered their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Canaccord Genuity Group cut their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a report on Monday, December 9th. Finally, Stephens upgraded STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $42.83.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.